Search results
Search for "phenethylamine" in Full Text gives 15 result(s) in Beilstein Journal of Organic Chemistry.
Facile one-pot reduction of β-nitrostyrenes to phenethylamines using sodium borohydride and copper(II) chloride
- Laura D’Andrea and
- Simon Jademyr
Beilstein J. Org. Chem. 2025, 21, 39–46, doi:10.3762/bjoc.21.4
- ; phenethylamine; Introduction The phenethylamine scaffold represents a recurring motif among natural and synthetic drug molecules. The latter are mainly constituted by a varied class of substituted phenylethylamines exhibiting psychoactive properties, and typically employed for medical and recreational use [1][2
- limited, since a NaBH4/transition metal salt system is mostly used to reduce nitroarenes [23][24][25][26]. One of the reported methods takes advantage of titanium(IV) isopropoxide as a catalyst to prepare varied β-phenethylamine analogues. Despite its simplicity, the reaction time is quite prolonged (from
- crucial role in the synthesis of phenethylamine analogues via this method. Dithering before the addition of the copper solution leads to the formation of Micheal adducts, which decrease the product yields. This phenomenon is due to the nature of β-nitrostyrenes, displaying considerable delocalization
Graphical Abstract
Scheme 1: Brief comparison between the main traditional synthetic routes for the preparation of substituted p...
Figure 1: The β-nitrostyrene analogues used in this work.
Scheme 2: Additional products obtained via this method: nitrobenzene and methyl benzoate are reduced in excel...
Figure 2: Numerous masses (m/z) were detected by ESI-MS at T = 0 upon mixing all the reagents to produce 1b.
Figure 3: Structures of proposed adducts. Their masses, 254.2 and 242.2, respectively, were found at T = 0 by...
Scheme 3: Proposed mechanism for the formation of the hydroxylamine side product b. N-Phenethylhydroxylamine (...
5th International Symposium on Synthesis and Catalysis (ISySyCat2023)
- Anthony J. Burke and
- Elisabete P. Carreiro
Beilstein J. Org. Chem. 2024, 20, 2704–2707, doi:10.3762/bjoc.20.227
- reported that imidazole analogs behaved differently due to the ʟ-histidine unit representing a nonphenyl scaffold. Some important data on the bioisosteric modifications of 2-phenethylamine derivatives, focusing on their affinity and core aromatic diversity, were included. In another Review article
2-Heteroarylethylamines in medicinal chemistry: a review of 2-phenethylamine satellite chemical space
- Carlos Nieto,
- Alejandro Manchado,
- Ángel García-González,
- David Díez and
- Narciso M. Garrido
Beilstein J. Org. Chem. 2024, 20, 1880–1893, doi:10.3762/bjoc.20.163
- area of chemical space of biological importance) in medicinal chemistry is the 2-phenethyl moiety, a key component of diverse drug-like entities. Although the core 2-phenethylamine structure has been recognized by the drug discovery community, little attention has been given to the various ring-based
- examples, which will be a valuable repository of phenyl, heteroaryl, and other replacement units of high value to the drug discovery community. Keywords: bioisosteres; 2-heteroarylethylamines; medicinal chemistry; 2-phenethylamine; scaffold hopping; Introduction One of the major hit-2-lead exploration
- affinity to key phenethylamine targets like adrenergic or histamine-type receptors, but also to novel ones such as TAAR1 (trace-amine-associated receptor 1), σ1/2 (sigma receptors 1 and 2), or AChE (acetylcholinesterase). Similar to our previous review, a descriptive, simple scope is presented below to
Graphical Abstract
Scheme 1: Description of the 2-heteroarylethylamine scope of the present review featuring appropriate heteroa...
Scheme 2: 2-Aminoethylpyridine derivatives with therapeutic activity.
Scheme 3: 2-Aminoethylfuran derivatives with therapeutic activity.
Scheme 4: 2-Aminoethylthiophene derivatives with therapeutic activity, part 1.
Scheme 5: 2-Aminoethylthiophene derivatives with therapeutic activity, part 2.
Scheme 6: 2-Aminoethylthiophene derivatives with therapeutic activity, part 3.
Scheme 7: 2-Aminoethylpyrrole derivatives with therapeutic activity.
Scheme 8: Histamine metabolic pathway.
Scheme 9: 2-Aminoethylimidazole derivatives with therapeutic activity, part 1. Krel is referred as histamine ...
Scheme 10: Conformationally restricted 2-aminoethylimidazole derivatives with therapeutic activity, part 2.
Scheme 11: 2-Aminoethylimidazole derivatives with therapeutic activity, part 3.
Scheme 12: 2-Aminoethylimidazole derivatives with therapeutic activity, part 4.
Scheme 13: 2-Aminoethylpyrazole derivatives with therapeutic activity.
Scheme 14: 2-Aminoethylisoxazole derivatives with therapeutic activity.
Scheme 15: 2-Aminoethylthiazole derivatives with therapeutic activity.
Scheme 16: 2-Aminoethyloxadiazole derivatives with therapeutic activity.
Scheme 17: 2-Aminoethyltriazole derivatives with therapeutic activity.
Scheme 18: 2-Aminoethyloxadiazole derivatives with therapeutic activity.
Synthesis and biological evaluation of Argemone mexicana-inspired antimicrobials
- Jessica Villegas,
- Bryce C. Ball,
- Katelyn M. Shouse,
- Caleb W. VanArragon,
- Ashley N. Wasserman,
- Hannah E. Bhakta,
- Allen G. Oliver,
- Danielle A. Orozco-Nunnelly and
- Jeffrey M. Pruet
Beilstein J. Org. Chem. 2023, 19, 1511–1524, doi:10.3762/bjoc.19.108
- generated via reductive amination of a substituted benzaldehyde and a substituted phenethylamine [30]. Thus, a variety of substituted berberine variants were rapidly generated as shown in Scheme 2. Our first variant (B1) resulted from the reductive amination of m-anisaldehyde with 3-methoxyphenethylamine
Graphical Abstract
Figure 1: Zones of inhibition for 1 mg of evaporated methanolic (MeOH) extracts from various parts of the A. ...
Scheme 1: General route to berberine variants, displaying the numbering system for the berberine ring.
Scheme 2: Synthesis of new berberine variants. Reductive amination to a secondary amine was followed by cycli...
Figure 2: X-ray crystal structures of the oxidation byproducts a) B4 (CCDC 2271457) and b) B6 (CCDC 2271458; ...
Scheme 3: Direct modification of the original berberine structure.
Scheme 4: Preparation of non-cyclic charged variants of B1.
Scheme 5: Partial reduction of compound B1 to B14.
Figure 3: Kirby–Bauer zones of inhibition for all variants B1–B14 compared to original berberine (B). Mean zo...
Scheme 6: Synthesis of the substituted 2-bromoaminonaphthalenes 9 and 10.
Scheme 7: Completion of the synthesis of variants C1–C4.
Figure 4: Kirby–Bauer zones of inhibition for variants C1–C4 compared to original chelerythrine (C). Mean zon...
Figure 5: Effects of original berberine and all variants against T84 human colon cancer cells. Cells were tre...
Figure 6: Effects of original chelerythrine and all variants against T84 human colon cancer. Cells were treat...
Eschenmoser coupling reactions starting from primary thioamides. When do they work and when not?
- Lukáš Marek,
- Jiří Váňa,
- Jan Svoboda and
- Jiří Hanusek
Beilstein J. Org. Chem. 2023, 19, 808–819, doi:10.3762/bjoc.19.61
- group. The leaving abilities of "aniline" nitrogen (anilinium has a pKa = 4.60 in water) [22] in intermediate 16 (Scheme 7) and "phenethylamine" nitrogen (2-phenyl-2-propylammonium has a pKa = 10.38 in water) [34] in 7a (Scheme 3) must differ by several orders of magnitude, which makes the irreversible
- , then the Hantzsch cyclization pathway can occur, and the structure of the product depends on the leaving ability of the lactam/amide nitrogen. A good leaving “aniline” group prefers C–N cleavage, whereas the worse leaving “phenethylamine” prefers water elimination. Experimental The starting 1,1
Graphical Abstract
Scheme 1: Eschenmoser coupling reaction between 3-substituted oxindoles and thioamides.
Scheme 2: Possible reactions of α-haloketones, esters and amides with primary thioamides.
Figure 1: Studied α-bromoamides and α-bromolactams.
Scheme 3: Reaction of 4-bromo-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one (2b) with thiobenzamide and thioa...
Scheme 4: Reaction of 4-bromo-1,1-dimethyl-1,4-dihydroisoquinolin-3(2H)-one (2b) with 4’-substituted thiobenz...
Scheme 5: Reaction of 4-bromoisoquinoline-1,3(2H,4H)-dione (3) with thiobenzamide, thioacetamide, and thioben...
Scheme 6: Reaction of N-phenyl- and N-methyl-2-bromo(phenyl)acetamide (4a,b) with thiobenzamide in acetonitri...
Scheme 7: Transformation of salt 15 under kinetic and thermodynamic control conditions [1].
Figure 2: Comparison of energy profiles (relative Gibbs energies at 298 K in kJ·mol−1 for the ECR (right) and...
1,2-Naphthoquinone-4-sulfonic acid salts in organic synthesis
- Ruan Carlos B. Ribeiro,
- Patricia G. Ferreira,
- Amanda de A. Borges,
- Luana da S. M. Forezi,
- Fernando de Carvalho da Silva and
- Vitor F. Ferreira
Beilstein J. Org. Chem. 2022, 18, 53–69, doi:10.3762/bjoc.18.5
- phenethylamine derivatives (amphetamine, methamphetamine, 2,5-dimethoxy-4-methylamphetamine, mescaline, ephedrine, and norephedrine). The reaction products were separated by thin-layer chromatography and analyzed by elemental analysis, nuclear magnetic resonance, infrared spectroscopy, and mass spectrometry. In
Graphical Abstract
Figure 1: Naphthoquinones are commonly used in organic synthesis.
Figure 2: Some important natural and synthetic naphthoquinones.
Scheme 1: Synthetic studies of BNQs and reactions with amines.
Scheme 2: Methods described for the synthesis of β-NQS.
Figure 3: Drugs detected using β-NQSNa.
Scheme 3: Reactions between β-NQS and amines.
Scheme 4: Isomerization of 4-arylamino-1,2-naphthoquinones.
Scheme 5: Synthesis of unsymmetrical 2-amino-4-imino compounds.
Scheme 6: Synthesis of bis(isoxazolyl)naphthoquinones from β-NQS.
Scheme 7: The reaction of β-NQS with 30 followed by cycle condensation.
Scheme 8: Synthesis of 4-(2-amino-5-selenothiazoles)-1,2-naphthoquinones.
Scheme 9: Synthesis of amino- and phenoxy-1,2-naphthoquinones.
Scheme 10: Synthesis of 4-semicarbazide-1,2-naphthoquinone.
Scheme 11: Reactions of 4-azido-1,2-naphthoquinone.
Figure 4: Modifications that can be easily carried out from the products of β-NQS 8.
Scheme 12: Derivatives of 1,2-naphthoquinones obtained from β-NQS.
Scheme 13: Oximes as well as 4-amino- and 4-phenoxy-1,2-naphthoquinone as potential anti-inflammatory agents.
Scheme 14: Synthesis of triazoles from β-NQS.
Scheme 15: Synthesis of naphtho[1,2-d]oxazoles from β-NQS.
Scheme 16: A) Arylation and vinylation of β-NQS catalyzed by Ni(II) salts. B) Transformation of the 1,2-dicarb...
Scheme 17: Benzo[a]carbazole and benzo[c]carbazoles fused with 1,2-naphthoquinone.
Scheme 18: Synthesis of 1,2-naphthoquinones having a C=C bond from β-NQS. Method A: NaOH, EtOH/H2O, 40 °C, 2 h...
Scheme 19: C=C bond formation from β-NQS and substituted acetonitriles.
Isolation and characterization of new phenolic siderophores with antimicrobial properties from Pseudomonas sp. UIAU-6B
- Emmanuel T. Oluwabusola,
- Olusoji O. Adebisi,
- Fernando Reyes,
- Kojo S. Acquah,
- Mercedes De La Cruz,
- Larry L. Mweetwa,
- Joy E. Rajakulendran,
- Digby F. Warner,
- Deng Hai,
- Rainer Ebel and
- Marcel Jaspars
Beilstein J. Org. Chem. 2021, 17, 2390–2398, doi:10.3762/bjoc.17.156
- through deviation of the salimethyloxazolinyl-thioester intermediate 8 from the assembly line via an unusually facile C–N-bond opening of the ring to generate an ester bond, and followed directly by amination (+ NH3), the addition of histamine and phenethylamine units to form compounds 1, 2, and 3
- , respectively (Figure 3). Biochemical studies show that histamine and phenethylamine moieties were produced from histidine and phenylalanine substrates by a decarboxylase enzyme [41][42][43]. Pseudomobactin A (4) was proposed logically to have formed through direct amination of the unstable salimethyloxazolinyl
Graphical Abstract
Figure 1: Structures of the new phenolic siderophores 1–5, pseudomonine (6), and salicylic acid (7).
Figure 2: Key HMBC and 1H-1H COSY correlations.
Figure 3: Plausible biosynthetic hypotheses of compounds 1–5.
Synthetic accesses to biguanide compounds
- Oleksandr Grytsai,
- Cyril Ronco and
- Rachid Benhida
Beilstein J. Org. Chem. 2021, 17, 1001–1040, doi:10.3762/bjoc.17.82
- cyanoguanidines and amine hydrochlorides: One example of the direct fusion of a phenethylamine hydrochloride derivative and a substituted cyanoguanidine has been recently disclosed by Kim et al. (Scheme 15) [27]. After 2 h reaction time, the yield proved excellent. Heating of substituted cyanoguanidines and
Graphical Abstract
Figure 1: Tautomeric forms of biguanide.
Figure 2: Illustrations of neutral, monoprotonated, and diprotonated structures biguanide.
Figure 3: The main approaches for the synthesis of biguanides. The core structure is obtained via the additio...
Scheme 1: The three main preparations of biguanides from cyanoguanidine.
Scheme 2: Synthesis of butylbiguanide using CuCl2 [16].
Scheme 3: Synthesis of biguanides by the direct fusion of cyanoguanidine and amine hydrochlorides [17,18].
Scheme 4: Synthesis of ethylbiguanide and phenylbiguanide as reported by Smolka and Friedreich [14].
Scheme 5: Synthesis of arylbiguanides through the reaction of cyanoguanidine with anilines in water [19].
Scheme 6: Synthesis of aryl- and alkylbiguanides by adaptations of Cohn’s procedure [20,21].
Scheme 7: Microwave-assisted synthesis of N1-aryl and -dialkylbiguanides [22,23].
Scheme 8: Synthesis of aryl- and alkylbiguanides by trimethylsilyl activation [24,26].
Scheme 9: Synthesis of phenformin analogs by TMSOTf activation [27].
Scheme 10: Synthesis of N1-(1,2,4-triazolyl)biguanides [28].
Scheme 11: Synthesis of 2-guanidinobenzazoles by addition of ortho-substituted anilines to cyanoguanidine [30,32] and...
Scheme 12: Synthesis of 2,4-diaminoquinazolines by the addition of 2-cyanoaniline to cyanoguanidine and from 3...
Scheme 13: Reactions of anthranilic acid and 2-mercaptobenzoic acid with cyanoguanidine [24,36,37].
Scheme 14: Synthesis of disubstituted biguanides with Cu(II) salts [38].
Scheme 15: Synthesis of an N1,N2,N5-trisubstituted biguanide by fusion of an amine hydrochloride and 2-cyano-1...
Scheme 16: Synthesis of N1,N5-disubstituted biguanides by the addition of anilines to cyanoguanidine derivativ...
Scheme 17: Microwave-assisted additions of piperazine and aniline hydrochloride to substituted cyanoguanidines ...
Scheme 18: Synthesis of N1,N5-alkyl-substituted biguanides by TMSOTf activation [27].
Scheme 19: Additions of oxoamines hydrochlorides to dimethylcyanoguanidine [49].
Scheme 20: Unexpected cyclization of pyridylcyanoguanidines under acidic conditions [50].
Scheme 21: Example of industrial synthesis of chlorhexidine [51].
Scheme 22: Synthesis of symmetrical N1,N5-diarylbiguanides from sodium dicyanamide [52,53].
Scheme 23: Synthesis of symmetrical N1,N5-dialkylbiguanides from sodium dicyanamide [54-56].
Scheme 24: Stepwise synthesis of unsymmetrical N1,N5-trisubstituted biguanides from sodium dicyanamide [57].
Scheme 25: Examples for the synthesis of unsymmetrical biguanides [58].
Scheme 26: Examples for the synthesis of an 1,3-diaminobenzoquinazoline derivative by the SEAr cyclization of ...
Scheme 27: Major isomers formed by the SEAr cyclization of symmetric biguanides derived from 2- and 3-aminophe...
Scheme 28: Lewis acid-catalyzed synthesis of 8H-pyrrolo[3,2-g]quinazoline-2,4-diamine [63].
Scheme 29: Synthesis of [1,2,4]oxadiazoles by the addition of hydroxylamine to dicyanamide [49,64].
Scheme 30: Principle of “bisamidine transfer” and analogy between the reactions with N-amidinopyrazole and N-a...
Scheme 31: Representative syntheses of N-amidino-amidinopyrazole hydrochloride [68,69].
Scheme 32: First examples of biguanide syntheses using N-amidino-amidinopyrazole [66].
Scheme 33: Example of “biguanidylation” of a hydrazide substrate [70].
Scheme 34: Example for the synthesis of biguanides using S-methylguanylisothiouronium iodide as “bisamidine tr...
Scheme 35: Synthesis of N-substituted N1-cyano-S-methylisothiourea precursors.
Scheme 36: Addition routes on N1-cyano-S-methylisothioureas.
Scheme 37: Synthesis of an hydroxybiguanidine from N1-cyano-S-methylisothiourea [77].
Scheme 38: Synthesis of an N1,N2,N3,N4,N5-pentaarylbiguanide from the corresponding triarylguanidine and carbo...
Scheme 39: Reactions of N,N,N’,N’-tetramethylguanidine (TMG) with carbodiimides to synthesize hexasubstituted ...
Scheme 40: Microwave-assisted addition of N,N,N’,N’-tetramethylguanidine to carbodiimides [80].
Scheme 41: Synthesis of N1-aryl heptasubstituted biguanides via a one-pot biguanide formation–copper-catalyzed ...
Scheme 42: Formation of 1,2-dihydro-1,3,5-triazine derivatives by the reaction of guanidine with excess carbod...
Scheme 43: Plausible mechanism for the spontaneous cyclization of triguanides [82].
Scheme 44: a) Formation of mono- and disubstituted (iso)melamine derivatives by the reaction of biguanides and...
Scheme 45: Reactions of 2-aminopyrimidine with carbodiimides to synthesize 2-guanidinopyrimidines as “biguanid...
Scheme 46: Non-catalyzed alternatives for the addition of 2-aminopyrimidine derivatives to carbodiimides. A) h...
Scheme 47: Addition of guanidinomagnesium halides to substituted cyanamides [90].
Scheme 48: Microwave-assisted synthesis of [11C]metformin by the reaction of 11C-labelled dimethylcyanamide an...
Scheme 49: Formation of 4-amino-6-dimethylamino[1,3,5]triazin-2-ol through the reaction of Boc-guanidine and d...
Scheme 50: Formation of 1,3,5-triazine derivatives via the addition of guanidines to substituted cyanamides [92].
Scheme 51: Synthesis of biguanide by the reaction of O-alkylisourea and guanidine [93].
Scheme 52: Aromatic nucleophilic substitution of guanidine on 2-O-ethyl-1,3,5-triazine [95].
Scheme 53: Synthesis of N1,N2-disubstituted biguanides by the reaction of guanidine and thioureas in the prese...
Scheme 54: Cyclization reactions involving condensations of guanidine(-like) structures with thioureas [97,98].
Scheme 55: Condensations of guanidine-like structures with thioureas [99,100].
Scheme 56: Condensations of guanidines with S-methylisothioureas [101,102].
Scheme 57: Addition of 2-amino-1,3-diazaaromatics to S-alkylisothioureas [103,104].
Scheme 58: Addition of guanidines to 2-(methylsulfonyl)pyrimidines [105].
Scheme 59: An example of a cyclodesulfurization reaction to a fused 3,5-diamino-1,2,4-triazole [106].
Scheme 60: Ring-opening reactions of 1,3-diaryl-2,4-bis(arylimino)-1,3-diazetidines [107].
Scheme 61: Formation of 3,5-diamino-1,2,4-triazole derivatives via addition of hydrazines to 1,3-diazetidine-2...
Scheme 62: Formation of a biguanide via the addition of aniline to 1,2,4-thiadiazol-3,5-diamines, ring opening...
Figure 4: Substitution pattern of biguanides accessible by synthetic pathways a–h.
From dipivaloylketene to tetraoxaadamantanes
- Gert Kollenz and
- Curt Wentrup
Beilstein J. Org. Chem. 2018, 14, 1–10, doi:10.3762/bjoc.14.1
- exhibit axial chirality [21], as has been demonstrated by 1H NMR spectroscopy using the optically active shift reagent Eu(hfc)3 [19]. The enantiomers of the dicarboxylic acid 11 have been separated by flash chromatography of their diastereomeric salts with 1-phenethylamine, and the structures of the acids
Graphical Abstract
Scheme 1: Synthetic routes to 2,4,6,8-tetraoxaadamantanes.
Scheme 2: Conversion of dipivaloylketene (2) to bisdioxines (2,6,9-trioxabicyclo[3.3.1]nona-3,7-dienes) 4 and...
Scheme 3: 2,6,9-Trioxabicyclo[3.3.1]nonadienes (bisdioxines, 9–13) derived from dipivaloylketene (2).
Scheme 4: Mechanisms of formation of bisdioxine acid derivatives from dimer 3.
Scheme 5: Recently reported synthesis of chromenobisdioxines.
Scheme 6: Formation of tetraoxaadamantanes.
Scheme 7: Decarboxylative hydrolysis and oxa-Michael-type ring closure.
Scheme 8: Oxime and hydrazine derivatives of bisdioxines and tetraoxaadamantanes.
Figure 1: Bistetraoxaadamantane derivatives.
Scheme 9: Inward-pointing isocyanate, urethane and carbamate groups in bisdioxines. The diisocyanate is obtai...
Scheme 10: Microwave-assisted tetraoxaadamantane formation.
Scheme 11: Cyclic bisdioxine ester derivative 34 forming a single mono-tetraoxaadamantane.
Figure 2: Cyclic bisdioxine derivative not forming a tetraoxaadamantane due to reduced cavity size.
Figure 3: The bisdioxine-calix[6]arene derivative 37 complexes Cs+ but does not form a tetraoxaadamantane der...
Quinone-catalyzed oxidative deformylation: synthesis of imines from amino alcohols
- Xinyun Liu,
- Johnny H. Phan,
- Benjamin J. Haugeberg,
- Shrikant S. Londhe and
- Michael D. Clift
Beilstein J. Org. Chem. 2017, 13, 2895–2901, doi:10.3762/bjoc.13.282
- . Phenethylamine (6q) provided only a 17% yield of the corresponding imine (7q, Table 3, entry 7), potentially due to its increased nucleophilicity, which may result in inhibition of catalysis via condensation with quinone 2c. We also tested several electron deficient amides (6r−t) in these reactions (Table 3
Graphical Abstract
Scheme 1: Established methods for the preparation of imines vs this work.
Scheme 2: Proposed catalytic cycle for quinone-catalyzed deformylation.
Scheme 3: Studies of quinone-catalyzed C−C bond cleavage in related substrates.
Scheme 4: Sequential oxidative deformylation/Mukaiyama−Mannich addition using phenylglycinol.
Brønsted acid-mediated cyclization–dehydrosulfonylation/reduction sequences: An easy access to pyrazinoisoquinolines and pyridopyrazines
- Ramana Sreenivasa Rao and
- Chinnasamy Ramaraj Ramanathan
Beilstein J. Org. Chem. 2017, 13, 428–440, doi:10.3762/bjoc.13.46
- the reported procedure [39]. The N-protected N-phenethylpiperazine-2,6-dione 8h was formed, while treating the potassium salt of N-benzyliminodiacetic acid with phenethylamine in presence of CDI in THF under reflux conditions. Similarly, this strategy has been extended to couple arylethylamines with
Graphical Abstract
Figure 1: Selected active pyrazinoisoquinolines, 2-oxopiperazines and aldose reductase inhibitors (ALR2).
Scheme 1: Comparison of previous reports with present work for piperazine-2,6-dione synthesis.
Scheme 2: Coupling of N-benzenesulfonyliminodiacetic acid with primary amines using CDI/DMAP.
Scheme 3: Formation of ene-diamides 9a–g and pyrazinones 10a–f.
Scheme 4: Mechanism for the formation of substituted pyrazinones.
Figure 2: HRMS spectra of aliquot generated from cyclization reaction of 7c.
Figure 3: ORTEP diagrams of compound 9b and 10a.
Scheme 5: Synthesis of 3-phenylpyrazinone.
Scheme 6: Synthesis of 4-N-benzyl-1-N-(aryl/heteroarylethyl)piperazine-2,6-dione.
Scheme 7: Cyclization of pyrazinoisoquinolines.
Scheme 8: Synthesis of the drug praziquantel 1.
Phosphated cyclodextrins as water-soluble chiral NMR solvating agents for cationic compounds
- Cira Mollings Puentes and
- Thomas J. Wenzel
Beilstein J. Org. Chem. 2017, 13, 43–53, doi:10.3762/bjoc.13.6
- structural features are examined and enantiomeric differentiation obtained with P-CDs is compared to prior results acquired with CM-CDs. Results and Discussion Thirty-three substrates including α-methylbenzylamine (1), N,α-dimethylbenzylamine (2), N,N-dimethyl-1-phenethylamine (3), N-allyl-α
Graphical Abstract
Figure 1: Structure of cyclodextrins (CD) and their carboxymethylated (CM-CD) and phosphated (P-CD) derivativ...
Figure 2: Structures of substrates included in the study. All compounds were examined in their protonated for...
Figure 3: The (a) C-methyl resonance of 3 (10 mM, enriched in the (R)-enantiomer) in the presence of (b) P-α-...
Figure 4: The (a) methine resonance of the carbinol carbon (5.124 ppm) and N-methyl resonance (2.768 ppm) of 7...
Figure 5: The N-methyl resonance of 7 (10 mM, enriched in (1S,2R)-enantiomer) with P-β-CD-LDS (20 mM) and con...
Recent developments in copper-catalyzed radical alkylations of electron-rich π-systems
- Kirk W. Shimkin and
- Donald A. Watson
Beilstein J. Org. Chem. 2015, 11, 2278–2288, doi:10.3762/bjoc.11.248
- phenethylamine derivatives, many of which possess known biological activity. For instance, reduction of the fully substituted nitroalkane 19 provides phentermine (20), a clinically prescribed appetite suppressant (Scheme 4) [29][30]. While the precise mechanism of this transformation is not fully understood
Graphical Abstract
Scheme 1: Reactivity of nitronate anions towards alkyl electrophiles.
Scheme 2: Ligands tested in the alkylation of nitroalkanes with alkyl halides. aNaOt-Bu as base, hexanes as s...
Scheme 3: Scope of the copper-catalyzed nitroalkane benzylation.
Scheme 4: Application of the nitro-alkylation reaction to the synthesis of phentermine.
Scheme 5: Possible mechanism of the thermal redox process.
Scheme 6: Scope of the reaction of nitroalkanes with α-bromocarbonyls.
Scheme 7: Synthesis of highly congested β-amino acids.
Scheme 8: Copper-catalyzed alkenylation reactions.
Scheme 9: Proposed mechanism of the copper-catalyzed alkenylation reaction.
Scheme 10: Scope of the copper-catalyzed alkenylation of tertiary electrophiles.
Scheme 11: Scope of the exo-methylene styrene synthesis.
Scheme 12: Phenol-directed synthesis of Z-alkenes.
Scheme 13: Scope of the phenol-directed Z-alkene synthesis.
Scheme 14: Rationale for the formal [3 + 2] cycloaddition.
Scheme 15: Scope of the formal [3 + 2] cycloaddition.
Scheme 16: Benzylation of styrenes using copper catalysis.
Scheme 17: Copper-catalyzed carboiodination of alkynes.
Scheme 18: Copper-catalyzed trans-carbohalogenation of alkynes. aNaI (2 equiv) was added.
trans-2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans-2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT2 receptor family
- Adam Pigott,
- Stewart Frescas,
- John D. McCorvy,
- Xi-Ping Huang,
- Bryan L. Roth and
- David E. Nichols
Beilstein J. Org. Chem. 2012, 8, 1705–1709, doi:10.3762/bjoc.8.194
- than for DOI itself. Keywords: cyclopropanation; diazomethane; hallucinogen; 5-HT2A agonist; receptor probe; trans-2-phenylcyclopropylamines; Introduction Among the molecules that have proven very valuable to neuroscientists studying brain serotonin systems is the substituted phenethylamine
Graphical Abstract
Figure 1: Structures of well-known serotonin 5-HT2A agonists 1a,b, 2, and 3, and compounds 4 and 5 reported i...
Scheme 1: Synthesis of arylcyclopropane carboxylic acids from the corresponding cinnamic acids, followed by h...
Scheme 2: Conversion of arylcyclopropane carboxylic acids 10a,b to the amines 4 and 5, and chemical resolutio...
Scheme 3: Chemical resolution of arylcyclopropane carboxylic acid 9 followed by bromination.
Molecular recognition of organic ammonium ions in solution using synthetic receptors
- Andreas Späth and
- Burkhard König
Beilstein J. Org. Chem. 2010, 6, No. 32, doi:10.3762/bjoc.6.32
- binding constant of 7.8 × 103 M−1 was found for the complex of phenyl substituted (R,R)-30 with the R-enantiomer of the guest. Chiral side arms derived from phenethylamine attached to diaza-18-crown-6 ethers 31 (Figure 17) effectively enable the molecular recognition of aromatic amino acid potassium and
Graphical Abstract
Figure 1: Biologically important amines and quaternary ammonium salts: histamine (1), dopamine (2) and acetyl...
Figure 2: Crown ether 18-crown-6.
Figure 3: Conformations of 18-crown-6 (4) in solvents of different polarity.
Figure 4: Binding topologies of the ammonium ion depending on the crown ring size.
Figure 5: A “pseudorotaxane” structure consisting of 24-crown-8 and a secondary ammonium ion (5); R = Ph.
Figure 6: Typical examples of azacrown ethers, cryptands and related aza macrocycles.
Figure 7: Binding of ammonium to azacrown ethers and cryptands [111-113].
Figure 8: A 19-crown-6-ether with decalino blocking groups (11) and a thiazole-dibenzo-18-crown-6-ether (12).
Figure 9: 1,3-Bis(6-oxopyridazin-1-yl)propane derivatives 13 and 14 by Campayo et al.
Figure 10: Fluorescent azacrown-PET-sensors based on coumarin.
Figure 11: Two different pyridino-cryptands (17 and 18) compared to a pyridino-crown (19); chiral ammonium ion...
Figure 12: Pyridino-18-crown-6 ligand (21), a similar acridino-18-crown-6 ligand (22) and a structurally relat...
Figure 13: Ciral pyridine-azacrown ether receptors 24.
Figure 14: Chiral 15-crown-5 receptors 26 and an analogue 18-crown-6 ligand 27 derived from amino alcohols.
Figure 15: C2-symmetric chiral 18-crown-6 amino alcohol derivatives 28 and related macrocycles.
Figure 16: Macrocycles with diamide-diester groups (30).
Figure 17: C2-symmetric chiral aza-18-crown-6 ethers (31) with phenethylamine residues.
Figure 18: Chiral C-pivot p-methoxy-phenoxy-lariat ethers.
Figure 19: Chiral lariat crown ether 34.
Figure 20: Sucrose-based chiral crown ether receptors 36.
Figure 21: Permethylated fructooligosaccharide 37 showing induced-fit chiral recognition.
Figure 22: Biphenanthryl-18-crown-6 derivative 38.
Figure 23: Chiral lariat crown ethers derived from binol by Fuji et al.
Figure 24: Chiral phenolic crown ether 41 with “aryl chiral barriers” and guest amines.
Figure 25: Chiral bis-crown receptor 43 with a meso-ternaphthalene backbone.
Figure 26: Chromogenic pH-dependent bis-crown chemosensor 44 for diamines.
Figure 27: Triamine guests for binding to receptor 44.
Figure 28: Chiral bis-crown phenolphthalein chemosensors 46.
Figure 29: Crown ether amino acid 47.
Figure 30: Luminescent receptor 48 for bis-alkylammonium guests.
Figure 31: Luminescent CEAA (49a), a bis-CEAA receptor for amino acids (49b) and the structure of lysine bindi...
Figure 32: Luminescent CEAA tripeptide for binding small peptides.
Figure 33: Bis crown ether 51a self assembles co-operatively with C60-ammonium ion 51b.
Figure 34: Triptycene-based macrotricyclic dibenzo-[24]-crown-8 ether host 52 and guests.
Figure 35: Copper imido diacetic acid azacrown receptor 53a and the suggested His-Lys binding motif; a copper ...
Figure 36: Urea (54) and thiourea (55) benzo crown receptor for transport and extraction of amino acids.
Figure 37: Crown pyryliums ion receptors 56 for amino acids.
Figure 38: Ditopic sulfonamide bridged crown ether receptor 57.
Figure 39: Luminescent peptide receptor 58.
Figure 40: Luminescent receptor 59 for the detection of D-glucosamine hydrochloride in water/ethanol and lumin...
Figure 41: Guanidinium azacrown receptor 61 for simple amino acids and ditopic receptor 62 with crown ether an...
Figure 42: Chiral bicyclic guanidinium azacrown receptor 63 and similar receptor 64 for the enantioselective t...
Figure 43: Receptors for zwitterionic species based on luminescent CEAAs.
Figure 44: 1,10-Azacrown ethers with sugar podand arms and the anticancer agent busulfan.
Figure 45: Benzo-18-crown-6 modified β-cyclodextrin 69 and β-cyclodextrin functionalized with diaza-18-crown-6...
Figure 46: Receptors for colorimetric detection of primary and secondary ammonium ions.
Figure 47: Porphyrine-crown-receptors 72.
Figure 48: Porphyrin-crown ether conjugate 73 and fullerene-ammonium ion guest 74.
Figure 49: Calix[4]arene (75a), homooxocalix[4]arene (75b) and resorcin[4]arene (75c) compared (R = H, alkyl c...
Figure 50: Calix[4]arene and ammonium ion guest (R = H, alkyl, OAcyl etc.), possible binding sites; A: co-ordi...
Figure 51: Typical guests for studies with calixarenes and related molecules.
Figure 52: Lower rim modified p-tert-butylcalix[5]arenes 82.
Figure 53: The first example of a water soluble calixarene.
Figure 54: Sulfonated water soluble calix[n]arenes that bind ammonium ions.
Figure 55: Displacement assay for acetylcholine (3) with a sulfonato-calix[6]arene (84b).
Figure 56: Amino acid inclusion in p-sulfonatocalix[4]arene (84a).
Figure 57: Calixarene receptor family 86 with upper and lower rim functionalization.
Figure 58: Calix[6]arenes 87 with one carboxylic acid functionality.
Figure 59: Sulfonated calix[n]arenes with mono-substitution at the lower rim systematically studied on their r...
Figure 60: Cyclotetrachromotropylene host (91) and its binding to lysine (81c).
Figure 61: Calixarenes 92 and 93 with phosphonic acids groups.
Figure 62: Calix[4]arene tetraphosphonic acid (94a) and a double bridged analogue (94b).
Figure 63: Calix[4]arene tetraphosphonic acid ester (92c) for surface recognition experiments.
Figure 64: Calixarene receptors 95 with α-aminophosphonate groups.
Figure 65: A bridged homocalix[3]arene 95 and a distally bridged homocalix[4]crown 96.
Figure 66: Homocalix[3]arene ammonium ion receptor 97a and the Reichardt’s dye (97b) for colorimetric assays.
Figure 67: Chromogenic diazo-bridged calix[4]arene 98.
Figure 68: Calixarene receptor 99 by Huang et al.
Figure 69: Calixarenes 100 reported by Parisi et al.
Figure 70: Guest molecules for inclusion in calixarenes 100: DAP × 2 HCl (101a), APA (101b) and Lys-OMe × 2 HC...
Figure 71: Different N-linked peptido-calixarenes open and with glycol chain bridges.
Figure 72: (S)-1,1′-Bi-2-naphthol calixarene derivative 104 published by Kubo et al.
Figure 73: A chiral ammonium-ion receptor 105 based on the calix[4]arene skeleton.
Figure 74: R-/S-phenylalaninol functionalized calix[6]arenes 106a and 106b.
Figure 75: Capped homocalix[3]arene ammonium ion receptor 107.
Figure 76: Two C3 symmetric capped calix[6]arenes 108 and 109.
Figure 77: Phosphorous-containing rigidified calix[6]arene 110.
Figure 78: Calix[6]azacryptand 111.
Figure 79: Further substituted calix[6]azacryptands 112.
Figure 80: Resorcin[4]arene (75c) and the cavitands (113).
Figure 81: Tetrasulfonatomethylcalix[4]resorcinarene (114).
Figure 82: Resorcin[4]arenes (115a/b) and pyrogallo[4]arenes (115c, 116).
Figure 83: Displacement assay for acetylcholine (3) with tetracyanoresorcin[4]arene (117).
Figure 84: Tetramethoxy resorcinarene mono-crown-5 (118).
Figure 85: Components of a resorcinarene based displacement assay for ammonium ions.
Figure 86: Chiral basket resorcin[4]arenas 121.
Figure 87: Resorcinarenes with deeper cavitand structure (122).
Figure 88: Resorcinarene with partially open deeper cavitand structure (123).
Figure 89: Water-stabilized deep cavitands with partially structure (124, 125).
Figure 90: Charged cavitands 126 for tetralkylammonium ions.
Figure 91: Ditopic calix[4]arene receptor 127 capped with glycol chains.
Figure 92: A calix[5]arene dimer for diammonium salt recognition.
Figure 93: Calixarene parts 92c and 129 for the formation molecular capsules.
Figure 94: Encapsulation of a quaternary ammonium cation by two resorcin[4]arene molecules (NMe4+@[75c]2 × Cl−...
Figure 95: Encapsulation of a quaternary ammonium cation by six resorcin[4]arene molecules (NMe3D+@[130]6 × Cl−...
Figure 96: Structure and schematic of cucurbit[6]uril (CB[6], 131a).
Figure 97: Cyclohexanocucurbit[6]uril (CB′[6], 132) and the guest molecule spermine (133).
Figure 98: α,α,δ,δ-Tetramethylcucurbit[6]uril (134).
Figure 99: Structure of the cucurbituril-phthalhydrazide analogue 135.
Figure 100: Organic cavities for the displacement assay for amine differentiation.
Figure 101: Displacement assay methodology for diammonium- and related guests involving cucurbiturils and some ...
Figure 102: Nor-seco-Cucurbituril (±)-bis-ns-CB[6] (140) and guest molecules.
Figure 103: The cucurbit[6]uril based complexes 141 for chiral discrimination.
Figure 104: Cucurbit[7]uril (131c) and its ferrocene guests (142) opposed.
Figure 105: Cucurbit[7]uril (131c) guest inclusion and representative guests.
Figure 106: Cucurbit[7]uril (131c) binding to succinylcholine (145) and different bis-ammonium and bis-phosphon...
Figure 107: Paraquat-cucurbit[8]uril complex 149.
Figure 108: Gluconuril-based ammonium receptors 150.
Figure 109: Examples of clefts (151a), tweezers (151b, 151c, 151d) and clips (151e).
Figure 110: Kemp’s triacid (152a), on example of Rebek’s receptors (152b) and guests.
Figure 111: Amino acid receptor (154) by Rebek et al.
Figure 112: Hexagonal lattice designed hosts by Bell et al.
Figure 113: Bell’s amidinium receptor (156) and the amidinium ion (157).
Figure 114: Aromatic phosphonic acids.
Figure 115: Xylene phosphonates 159 and 160a/b for recognition of amines and amino alcohols.
Figure 116: Bisphosphonate recognition motif 161 for a colorimetric assay with alizarin complexone (163) for ca...
Figure 117: Bisphosphonate/phosphate clip 164 and bisphosphonate cleft 165.
Figure 118: N-Methylpyrazine 166a, N-methylnicotinamide iodide (166b) and NAD+ (166c).
Figure 119: Bisphosphate cavitands.
Figure 120: Bisphosphonate 167 of Schrader and Finocchiaro.
Figure 121: Tweezer 168 for noradrenaline (80b).
Figure 122: Different tripods and heparin (170).
Figure 123: Squaramide based receptors 172.
Figure 124: Cage like NH4+ receptor 173 of Kim et al.
Figure 125: Ammonium receptors 174 of Chin et al.
Figure 126: 2-Oxazolin-based ammonium receptors 175a–d and 176 by Ahn et al.
Figure 127: Racemic guest molecules 177.
Figure 128: Tripods based on a imidazole containing macrocycle (178) and the guest molecules employed in the st...
Figure 129: Ammonium ion receptor 180.
Figure 130: Tetraoxa[3.3.3.3]paracyclophanes 181 and a cyclophanic tetraester (182).
Figure 131: Peptidic bridged paraquat-cyclophane.
Figure 132: Shape-selective noradrenaline host.
Figure 133: Receptor 185 for binding of noradrenaline on surface layers from Schrader et al.
Figure 134: Tetraphosphonate receptor for binding of noradrenaline.
Figure 135: Tetraphosphonate 187 of Schrader and Finocchiaro.
Figure 136: Zinc-Porphyrin ammonium-ion receptors 188 and 189 of Mizutani et al.
Figure 137: Zinc porphyrin receptor 190.
Figure 138: Zinc porphyrin receptors 191 capable of amino acid binding.
Figure 139: Zinc-porphyrins with amino acid side chains for stereoinduction.
Figure 140: Bis-zinc-bis-porphyrin based on Tröger’s base 193.
Figure 141: BINAP-zinc-prophyrin derivative 194 and it’s guests.
Figure 142: Bisaryl-linked-zinc-porphyrin receptors.
Figure 143: Bis-zinc-porphyrin 199 for diamine recognition and guests.
Figure 144: Bis-zinc-porphyrin crown ether 201.
Figure 145: Bis-zinc-porphyrin 202 for stereodiscrimination (L = large substituent; S = small substituent).
Figure 146: Bis-zinc-porphyrin[3]rotaxane and its copper complex and guests.
Figure 147: Dien-bipyridyl ligand 206 for co-ordination of two metal atoms.
Figure 148: The ligand and corresponding tetradentate co-complex 207 serving as enantioselective receptor for a...
Figure 149: Bis(oxazoline)–copper(II) complex 208 for the recognition of amino acids in aqueous solution.
Figure 150: Zinc-salen-complexes 209 for the recognition tertiary amines.
Figure 151: Bis(oxazoline)–copper(II) 211 for the recognition of amino acids in aqueous solution.
Figure 152: Zn(II)-complex of a C2 terpyridine crown ether.
Figure 153: Displacement assay and receptor for aspartate over glutamate.
Figure 154: Chiral complex 214 for a colorimetric displacement assay for amino acids.
Figure 155: Metal complex receptor 215 with tripeptide side arms.
Figure 156: A sandwich complex 216 and its displaceable dye 217.
Figure 157: Lanthanide complexes 218–220 for amino acid recognition.
Figure 158: Nonactin (221), valinomycin (222) and vancomycin (223).
Figure 159: Monesin (224a) and a chiral analogue for enantiodiscrimination of ammonium guests (224b).
Figure 160: Chiral podands (226) compared to pentaglyme-dimethylether (225) and 18-crown-6 (4).
Figure 161: Lasalocid A (228).
Figure 162: Lasalocid derivatives (230) of Sessler et al.
Figure 163: The Coporphyrin I tetraanion (231).
Figure 164: Linear and cyclic peptides for ammonium ion recognition.
Figure 165: Cyclic and bicyclic depsipeptides for ammonium ion recognition.
Figure 166: α-Cyclodextrin (136a) and novocaine (236).
Figure 167: Helical diol receptor 237 by Reetz and Sostmann.
Figure 168: Ammonium binding spherand by Cram et al. (238a) and the cyclic[6]metaphenylacetylene 238b in compar...
Figure 169: Receptor for peptide backbone and ammonium binding (239).
Figure 170: Anion sensor principle with 3-hydroxy-2-naphthanilide of Jiang et al.
Figure 171: 7-bromo-3-hydroxy-N-(2-hydroxyphenyl)naphthalene 2-carboxamide (241) and its amine binding.
Figure 172: Naturally occurring catechins with affinity to quaternary ammonium ions.
Figure 173: Spiropyran (244) and merocyanine form (244a) of the amino acid receptors of Fuji et al.
Figure 174: Coumarin aldehyde (245) and its iminium species with amino acid bound (245a) by Glass et al.
Figure 175: Coumarin aldehyde appended with boronic acid.
Figure 176: Quinolone aldehyde dimers by Glass et al.
Figure 177: Chromogenic ammonium ion receptors with trifluoroacetophenone recognition motifs.
Figure 178: Chromogenic ammonium ion receptor with trifluoroacetophenone recognition motif bound on different m...
